Emily Mason-Osann
Research Subjects
Emily Mason-Osann has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Ira Pastan
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
12 shared publications - Gerhard Niederfellner
Pharmaceutical Research and Early Development (pRED), Discovery Oncology, F. Hoffman-La Roche, Penzberg, Germany
8 shared publications - Kevin Hollevoet
PharmAbs, The KU Leuven Antibody Center – University of Leuven, Leuven, Belgium
8 shared publications - Sabine Imhof-Jung
Large Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
8 shared publications - Xiufen Liu
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute
8 shared publications - Adam Christopher Palmer
The University of North Carolina at Chapel Hill Department of Pharmacology, Computational Medicine Program, UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina
7 shared publications
Latest Publications
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Data from Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia
Combination therapy is an important part of cancer treatment and is often employed to overcome or prevent drug resistance. Preclinical screening strategies often prioritize synergistic drug combinations; however, studies of antibiotic combinations show that synergistic drug interactions can accelerate the emergence of resistance because resistance to one drug depletes the effect of both. In this study, we aimed to determine whether synergy drives the development of resistance in cancer cell lines using live-cell imaging. Consistent with prior models of tumor evolution, we found that when controlling for activity, drug synergy is associated with increased probability of developing drug resistance. We demonstrate that these observations are an expected consequence of synergy: the fitness benefit of resisting a drug in a combination is greater in synergistic combinations than in nonsynergistic combinations. These data have important implications for preclinical strategies aiming to develop novel combinations of cancer therapies with robust and durable efficacy.Significance:Preclinical strategies to identify combinations for cancer treatment often focus on identifying synergistic combinations. This study shows that in AML cells combinations that rely on synergy can increase the likelihood of developing resistance, suggesting that combination screening strategies may benefit from a more holistic approach rather than focusing on drug synergy.See related commentary by Bhola and Letai, p. 81.This article is featured in Selected Articles from This Issue, p. 80
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia
Combination therapy is an important part of cancer treatment and is often employed to overcome or prevent drug resistance. Preclinical screening strategies often prioritize synergistic drug combinations; however, studies of antibiotic combinations show that synergistic drug interactions can accelerate the emergence of resistance because resistance to one drug depletes the effect of both. In this study, we aimed to determine whether synergy drives the development of resistance in cancer cell lines using live-cell imaging. Consistent with prior models of tumor evolution, we found that when controlling for activity, drug synergy is associated with increased probability of developing drug resistance. We demonstrate that these observations are an expected consequence of synergy: the fitness benefit of resisting a drug in a combination is greater in synergistic combinations than in nonsynergistic combinations. These data have important implications for preclinical strategies aiming to develop novel combinations of cancer therapies with robust and durable efficacy.Significance:Preclinical strategies to identify combinations for cancer treatment often focus on identifying synergistic combinations. This study shows that in AML cells combinations that rely on synergy can increase the likelihood of developing resistance, suggesting that combination screening strategies may benefit from a more holistic approach rather than focusing on drug synergy.See related commentary by Bhola and Letai, p. 81.This article is featured in Selected Articles from This Issue, p. 80
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia
Supplementary Table 1 - Materials
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia
Supplementary Table 1 - Materials
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia
Supplementary Table 1 - Materials
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia
Supplementary Table 1 - Materials
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Data from Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia
Combination therapy is an important part of cancer treatment and is often employed to overcome or prevent drug resistance. Preclinical screening strategies often prioritize synergistic drug combinations; however, studies of antibiotic combinations show that synergistic drug interactions can accelerate the emergence of resistance because resistance to one drug depletes the effect of both. In this study, we aimed to determine whether synergy drives the development of resistance in cancer cell lines using live-cell imaging. Consistent with prior models of tumor evolution, we found that when controlling for activity, drug synergy is associated with increased probability of developing drug resistance. We demonstrate that these observations are an expected consequence of synergy: the fitness benefit of resisting a drug in a combination is greater in synergistic combinations than in nonsynergistic combinations. These data have important implications for preclinical strategies aiming to develop novel combinations of cancer therapies with robust and durable efficacy.Significance:Preclinical strategies to identify combinations for cancer treatment often focus on identifying synergistic combinations. This study shows that in AML cells combinations that rely on synergy can increase the likelihood of developing resistance, suggesting that combination screening strategies may benefit from a more holistic approach rather than focusing on drug synergy.See related commentary by Bhola and Letai, p. 81.This article is featured in Selected Articles from This Issue, p. 80
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia
Combination therapy is an important part of cancer treatment and is often employed to overcome or prevent drug resistance. Preclinical screening strategies often prioritize synergistic drug combinations; however, studies of antibiotic combinations show that synergistic drug interactions can accelerate the emergence of resistance because resistance to one drug depletes the effect of both. In this study, we aimed to determine whether synergy drives the development of resistance in cancer cell lines using live-cell imaging. Consistent with prior models of tumor evolution, we found that when controlling for activity, drug synergy is associated with increased probability of developing drug resistance. We demonstrate that these observations are an expected consequence of synergy: the fitness benefit of resisting a drug in a combination is greater in synergistic combinations than in nonsynergistic combinations. These data have important implications for preclinical strategies aiming to develop novel combinations of cancer therapies with robust and durable efficacy.Significance:Preclinical strategies to identify combinations for cancer treatment often focus on identifying synergistic combinations. This study shows that in AML cells combinations that rely on synergy can increase the likelihood of developing resistance, suggesting that combination screening strategies may benefit from a more holistic approach rather than focusing on drug synergy.See related commentary by Bhola and Letai, p. 81.This article is featured in Selected Articles from This Issue, p. 80
- Open Access
- 16 January 2024
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 5 (2) , 95-105
Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia
Combination therapy is an important part of cancer treatment and is often employed to overcome or prevent drug resistance. Preclinical screening strategies often prioritize synergistic drug combinations; however, studies of antibiotic combinations show that synergistic drug interactions can accelerate the emergence of resistance because resistance to one drug depletes the effect of both. In this study, we aimed to determine whether synergy drives the development of resistance in cancer cell lines using live-cell imaging. Consistent with prior models of tumor evolution, we found that when controlling for activity, drug synergy is associated with increased probability of developing drug resistance. We demonstrate that these observations are an expected consequence of synergy: the fitness benefit of resisting a drug in a combination is greater in synergistic combinations than in nonsynergistic combinations. These data have important implications for preclinical strategies aiming to develop novel combinations of cancer therapies with robust and durable efficacy. Significance: Preclinical strategies to identify combinations for cancer treatment often focus on identifying synergistic combinations. This study shows that in AML cells combinations that rely on synergy can increase the likelihood of developing resistance, suggesting that combination screening strategies may benefit from a more holistic approach rather than focusing on drug synergy. See related commentary by Bhola and Letai, p. 81. This article is featured in Selected Articles from This Issue, p. 80
- 16 January 2024
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 5 (2) , 95-105
Open AccessSynergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia
Combination therapy is an important part of cancer treatment and is often employed to overcome or prevent drug resistance. Preclinical screening strategies often prioritize synergistic drug combinations; however, studies of antibiotic combinations show that synergistic drug interactions can accelerate the emergence of resistance because resistance to one drug depletes the effect of both. In this study, we aimed to determine whether synergy drives the development of resistance in cancer cell lines using live-cell imaging. Consistent with prior models of tumor evolution, we found that when controlling for activity, drug synergy is associated with increased probability of developing drug resistance. We demonstrate that these observations are an expected consequence of synergy: the fitness benefit of resisting a drug in a combination is greater in synergistic combinations than in nonsynergistic combinations. These data have important implications for preclinical strategies aiming to develop novel combinations of cancer therapies with robust and durable efficacy. Significance: Preclinical strategies to identify combinations for cancer treatment often focus on identifying synergistic combinations. This study shows that in AML cells combinations that rely on synergy can increase the likelihood of developing resistance, suggesting that combination screening strategies may benefit from a more holistic approach rather than focusing on drug synergy. See related commentary by Bhola and Letai, p. 81. This article is featured in Selected Articles from This Issue, p. 80